BTK and acute myeloid leukemia: Recently the oral BTK inhibitor ibrutinib has been shown to inhibit AML blast proliferation, migration and leukaemic cell adhesion to bone marrow stromal cells in approximately 80% of primary samples tested, leading to the initiation of early phase clinical trials of ibrutinib in AML9, 23.